i) the expected impact of the acquisition on Techne's sales and net earnings, and (ii) the expected benefits of the acquisition on Techne's business and operations, involve risks and uncertainties that may affect actual results. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of Tocris into the Techne group of companies, the actual financial results of Tocris, the purchase price allocation of the acquisition, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has three subsidiaries, BiosPacific, Inc. (BiosPacific) located in Emeryville, California, Boston Biochem, Inc. (Boston Biochem) located in Cambridge, Massachusetts
'/>"/>
SOURCE Techne Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Techne Corporation Announces Acquisition2.
Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 20113.
Techne Corporation Announces That Dr. Roeland Nusse Has Accepted a Seat on Its Board of Directors4.
Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 20105.
Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 20096.
Techne Corporation Declares Dividend7.
TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell8.
Techne Corporation Board Member Recognized9.
Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors10.
Techne Corporation Announces That John L. Higgins has Accepted a Seat on Technes Board11.
Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009